Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance
08 1월 2024 - 10:00PM
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical
technology company focused on the development and commercialization
of innovative, minimally invasive solutions for patients with
obstructive sleep apnea, today announced certain preliminary,
unaudited results for the fourth quarter and full year ended
December 31, 2023, and provided its initial full year 2024
guidance.
Preliminary, Unaudited Fourth Quarter and Full Year 2023
Revenue and Recent Business Highlights
- Revenue for the fourth quarter of 2023 is anticipated to be in
the range of $192.3 million to $192.5 million, an
approximately 40% increase over the same quarter of 2022
- Revenue for full year 2023 is anticipated to be in the range of
$624.6 million to $624.8 million, an approximately 53%
increase over full year 2022
- Activated 78 new centers in the U.S. in the fourth quarter of
2023, bringing the total to 1,180 U.S. medical centers implanting
Inspire therapy
- Created 13 new sales territories in the U.S. in the fourth
quarter of 2023, bringing the total to 287 U.S. sales
territories
- Published 2023 Environmental, Social, and Governance (ESG)
Report
Initial Full Year 2024 Revenue Guidance
- Revenue for full year 2024 is anticipated to be in the range of
$775 million to $785 million, a 24% to 26% increase over full year
2023
“We are very pleased with our strong preliminary revenue
performance in the fourth quarter as the team executed
exceptionally well and finished the year with significant
momentum,” said Tim Herbert, President and Chief Executive Officer
of Inspire Medical Systems. “Throughout 2023, we demonstrated
improved operating leverage as our sales growth outpaced operating
expenses. As a result, we expect to announce a profitable fourth
quarter when we report our full financial results, currently
planned for February 6, 2024.”
The preliminary, unaudited revenue results described in this
press release are estimates only and are subject to revision until
Inspire reports its full financial results for 2023 in its Annual
Report on Form 10-K.
Inspire previously announced its participation in the 41st
Annual J.P. Morgan Healthcare Conference at the Westin St. Francis
Hotel in San Francisco, CA, including a formal company presentation
at 7:30 a.m. P.T. on Monday, January 8, 2024.
About Inspire Medical Systems
Inspire is a medical technology company focused on the
development and commercialization of innovative, minimally invasive
solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved
neurostimulation technology that provides a safe and effective
treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit
www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding our preliminary, unaudited fourth quarter and
full year results, and our expectations regarding full year 2024
financial outlook. In some cases, you can identify forward-looking
statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’
‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,”
“outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’
‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’
‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or
other similar expressions, although not all forward-looking
statements contain these words.
These forward-looking statements are based on management’s
current expectations and involve known and unknown risks and
uncertainties that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, estimates regarding the annual total addressable
market for our Inspire therapy in the U.S. and our market
opportunity outside the U.S.; future results of operations,
financial position, research and development costs, capital
requirements and our needs for additional financing; commercial
success and market acceptance of our Inspire therapy; the impact of
the ongoing and global COVID-19 pandemic; general and international
economic, political, and other risks, including currency and stock
market fluctuations and the uncertain economic environment; our
ability to achieve and maintain adequate levels of coverage or
reimbursement for our Inspire system or any future products we may
seek to commercialize; competitive companies and technologies in
our industry; our ability to enhance our Inspire system, expand our
indications and develop and commercialize additional products; our
business model and strategic plans for our products, technologies
and business, including our implementation thereof; our ability to
accurately forecast customer demand for our Inspire system and
manage our inventory; our dependence on third-party suppliers,
contract manufacturers and shipping carriers; consolidation in the
healthcare industry; our ability to expand, manage and maintain our
direct sales and marketing organization, and to market and sell our
Inspire system in markets outside of the U.S.; risks associated
with international operations; our ability to manage our growth;
our ability to increase the number of active medical centers
implanting Inspire therapy; our ability to hire and retain our
senior management and other highly qualified personnel; risk of
product liability claims; risks related to information technology
and cybersecurity; risk of damage to or interruptions at our
facilities; our ability to commercialize or obtain regulatory
approvals for our Inspire therapy and system, or the effect of
delays in commercializing or obtaining regulatory approvals; FDA or
other U.S. or foreign regulatory actions affecting us or the
healthcare industry generally, including healthcare reform measures
in the U.S. and international markets; and the timing or likelihood
of regulatory filings and approvals. Other important factors that
could cause actual results, performance or achievements to differ
materially from those contemplated in this press release can be
found under the captions “Risk Factors” and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations“ in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as updated in our Quarterly Report on Form
10-Q for the quarter ended September 30, 2023, and as such factors
may be updated from time to time in our other filings with the SEC,
which are accessible on the SEC’s website at www.sec.gov and the
Investors page of our website at www.inspiresleep.com. These and
other important factors could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, unless required by
applicable law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Thus, one should not
assume that our silence over time means that actual events are
bearing out as expressed or implied in such forward-looking
statements. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date of this press release.
Investor & Media Contact
Ezgi YagciVice President, Investor
Relationsezgiyagci@inspiresleep.com617-549-2443
Inspire Medical Systems (NYSE:INSP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Inspire Medical Systems (NYSE:INSP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024